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Abstract
Goals of work The aim of the study was to examine the
role of five general personality traits in fatigue in a group of
patients with breast cancer (BC) and a group with benign
breast problems (BBP).
Materials and methods Of the 304 participating women,
127 patients had BC and 177 BBP. A fatigue scale was
completed before diagnosis and 1, 3, and 6 months after
diagnosis (benign patients) or surgical treatment (BC
patients). A personality questionnaire (NEO-FFI) and a
depression scale (CES-D) were completed before diagnosis.
Main results The BC group was less tired before diagnosis,
more tired 1 month after diagnosis, and equally tired 3 and
6 months after diagnosis. In the total group, women were
more tired over time when they were more neurotic, less
agreeable, or more introverted. After controlling for
depressive symptoms, demographics, and medical factors,
baseline depressive symptoms (β=0.29, p<0.05), neuroti-
cism (β=0.29, p<0.05), and extraversion (β=−0.25, p<
0.05) predicted fatigue 6 months later. After also including
baseline fatigue, only neuroticism (β=0.22, p<0.05) and
baseline fatigue (β=0.79, p<0.001) predicted fatigue.
Conclusions Personality is more strongly related to fatigue
than demographics, the diagnosis cancer, receiving cancer
treatment, and baseline depressive symptoms and fatigue.
When replicated, screening and treating women who are at
risk to experience high levels of fatigue is recommended.
Keywords Breast neoplasm . Fatigue . Personality
Introduction
Breast cancer (BC) is the most common type of cancer
among women. In The Netherlands, 11% of all women will
develop carcinoma in situ or invasive carcinoma of the
breast [3]. A common reaction during and after the
treatment period is fatigue [1]. In general, BC patients are
not as severely tired as chronic fatigue syndrome patients
[24]: their fatigue is mainly mild to moderate [2]. However,
fatigue might distress BC patients [25], reduce their quality
of life (QOL) [29], and impair their physical activity [1].
The determinants of fatigue in BC patients are not yet
identified. Physical, cancer- or treatment-related factors
such as anemia [7], receiving chemotherapy [16], radio-
therapy [25], and/or hormone therapy only partially explain
the difference with fatigue in the general population.
Regarding the association between fatigue and personality
in (breast) cancer patients, inconsistent findings were
reported.
Nowadays, there is general agreement about the view
that personality, at least for descriptions at a rather global
level, can be described adequately in terms of the Big Five
dimensions: extraversion, agreeableness, conscientiousness,
emotional stability, and openness to experience [see, e.g.,
11, 12]. Extraversion reflects the disposition towards
cheerfulness, sociability, and high activity. Agreeableness
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represents the inclination towards interpersonal trust and
consideration of others. Conscientiousness summarizes the
tendency towards persistence, sense of duty, industrious-
ness, organizing, planning, and self-discipline. Emotional
stability stands for the tendency to experience no distress-
ing emotions such as fear, guilt, and frustration. Finally, the
fifth factor points at a receptive orientation towards varied
experiences and ideas [see 9 for a more detailed description
of these five basic factors]. In a recent cross-sectional study
among disease-free BC patients without depression, neu-
roticism and introversion were associated with higher levels
of fatigue [30]. In another recent cross-sectional study
among disease-free cancer patients, only neuroticism was
related to fatigue. However, it became non-significant when
depression and beliefs were added in the analyses [32].
Furthermore, no association was found between fatigue and
neuroticism or optimism in a prospective study among
patients with different types of cancer receiving radiother-
apy with curative intent [26]. When no additional variables
were included in the analyses, extraversion was, and
neuroticism was not, related to fatigue in another prospec-
tive study among patients with cancers of the breast or
prostate undergoing radical radiotherapy [29]. In a 3-month
follow-up study by this group, neither neuroticism nor
extraversion was associated with fatigue in patients with
prostate cancer receiving hormone therapy [28].
Most studies focussed on a small number of personality
traits, were cross-sectional, did not measure depression,
and/or did not include a comparison group [26, 28–30, 32].
The aim of this 6-month prospective follow-up study was to
examine the role of five general personality traits in fatigue
in patients having a palpable lump in the breast or being




Women with a palpable lump in the breast or an
abnormality on a screening mammography were referred
by their general practitioner to the department of surgery of
the outpatient clinics of the St. Elisabeth Hospital, Tilburg
(since 1 January, 2002) or Maasland Hospital, Sittard, The
Netherlands (since August, 2004). They were asked to
participate in a study with a pre- and post-treatment
prospective design, focussing on the role of personality in
patients’ QOL. Thus, the present study is part of a larger
study. When the women were asked to participate in the
study and completed the first set of questionnaires, it was
unknown whether a woman had BC or a benign breast
problem (BBP). Once diagnosis was known, diagnosis was
the reference point for subsequent measurement times for
benign patients. For BC patients, the reference point was
surgical treatment because otherwise follow-up measures
would interfere with timing of treatment modalities. Of the
eligible 533 women, 183 were later diagnosed with BC, and
305 appeared to have BBP. Exclusion criteria were
dementia, history of breast problems, and not being able
to read and speak standard Dutch. The study focussed on
women with BC who had a choice between breast
conserving treatment (BCT) and modified radical mastec-
tomy (MRM). Women with a breast tumor that was too
large to allow women to choose between BCT and MRM
were also excluded. Of the BC patients, 122 (66.7%)
participated in this study. Of the BBP group, 177 (58.0%)
agreed to participate. The most important reasons for not
participating were the length of the questionnaires and the
amount of stress the women experienced, which they felt
compromised concentration while completing the question-
naires. Women gave written informed consent. Women who
participated were younger than the non-participants [t(1,
530)=3.45, p<0.01]. They did not differ on diagnosis.
Measures
Women completed the questionnaires to assess fatigue four
times: before diagnosis (T1) and 1 (T2), 3 (T3), and 6 (T4)
months after diagnosis (benign patients) or surgical treatment
(BC patients). Personality and depressive symptoms were
measured once, before diagnosis. Questionnaires were com-
pleted at home or in the hospital, before their check up/visit.
Clinical parameters: tumor size after pathological exam-
ination and adjuvant treatment were obtained from the
medical records of the included patients.
The Fatigue Assessment Scale (FAS; [19]) is a fatigue
questionnaire consisting of ten items: five questions
reflecting physical fatigue and five questions assessing
mental fatigue. Although these two aspects of fatigue are
represented in the questionnaire, the FAS was unidimen-
sional when completed by a Dutch working population and
a representative group of the general population [19, 20], as
well as in sarcoidosis patients [10, 21]. The unidimensional
structure indicates that the FAS total score should be used.
The response scale is a 5-point scale (1, never to 5, always).
Scores on the FAS range from 10 to 50. The psychometric
properties are good in Dutch healthy individuals and
sarcoidosis patients [10, 20, 21]. In the BC patients,
Cronbach’s alpha internal consistency was 0.88, in the
BBP group 0.92. Factor analyses in both groups supported
the unidimensional nature of the scale (data not shown).
The Neuroticism-Extraversion-Openness Five Factor
Inventory (NEO-FFI; [9] Dutch version [15]) is developed
to study an individual’s personality. The following five
personality factors are tested: neuroticism, extraversion,
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openness, agreeableness, and conscientiousness. The psy-
chometric properties are good [9, 15].
The Center for Epidemiological Studies-Depression
Scale (CES-D [22]) is a 20-item scale designed to measure
the presence and degree of depressive symptoms. It has a 4-
point response scale. For the Dutch population, reliability
and criterion validity appeared to be good [4]. In the present
study, the 16-item CES-D as suggested by Schroevers et al.
[23] was used because they found it to be a more valid
assessment of depressive symptoms in both cancer patients
and healthy persons.
Data analysis
Frequencies were used to present the available demograph-
ic, medical, and psychological data. Participants who only
completed the first set of questionnaires were compared on
age, diagnosis, and kind of treatment with those who also
completed the fourth set 6 months later. Differences in
fatigue were examined between the BC and the BBP group
using t tests for each measurement point. Using repeated
measures, fatigue over time was investigated for the BC
and the BBP group, accounting for adjuvant treatment.
First, in the BC patient group, the relationship between
clinical parameters and fatigue was examined using t tests
(treatment with hormones, chemotherapy, radiotherapy, or
not), correlations (hospital stay in days), and analysis of
variance (ANOVA; tumor group). Following Cohen [8],
absolute correlations between 0.10 and 0.29 are considered
small, between 0.30 and 0.49 medium, and between 0.50
and higher as large. Then, the association between
demographics and fatigue were studied separately for the
BC and BBP group using t tests (having children or not,
having a partner or not, having a paid job or not, age >60 or
not), correlations (age), and ANOVA (education level).
Personality differences between the BC and BBP group
were examined using a multivariate ANOVA (MANOVA).
Eta squared between 0.01 and 0.06 is a small effect by
Cohen’s definition [8], between 0.06 and 0.13 a moderate
effect, and 0.14 or higher a large effect. The stability of
fatigue over 6 months was explored, differentiating high
and low scorers on the five personality factors in the total
group. For this purpose, we divided the total scores of each
NEO-five factor into two groups. The first group consisted
of the stanines ≤5; the second group of stanines ≥6. Finally,
the predictors of scores on fatigue 6 months after diagnosis/
surgical treatment were found using three regression
analyses (method enter). In the first analysis, demographic
characteristics (block 1), diagnosis (benign or BC), and ad-
juvant therapy (chemotherapy, radiotherapy, hormone thera-
py; block 2), and personality (block 3) were the independent
variables. In the second regression analysis, depressive symp-
toms were included in the third block and personality in the
fourth block. In the final analysis, a fifth block, consisting
of baseline fatigue, was incorporated. All p values were
two-tailed, and Statistical Package for the Social Sciences
(SPSS) 12.0 was used to perform all statistical analyses.
Results
Demographic and medical data are presented in Table 1. Of
the 299 included patients, 122 had BC, and 177 had BBPs.
Fifteen women in the BC group and 19 women in the BBP
group entered the study less than 6 months earlier. In
addition, 6 months after diagnosis (BBP) or surgical
treatment (BC), 63 (39.9%) with a benign diagnosis and
29 (27.1%) who were diagnosed with BC had dropped out
of the study. They did not differ on age, diagnosis,
chemotherapy, hormone therapy, radiotherapy, fatigue, and
personality from those who completed all questionnaires.
The BC group showed a different fatigue pattern over time
from the BBP group [Wilks Lambda=0.80, F(3, 137)=11.55,
p<0.001, partial eta squared 0.20; see Fig. 1]. They were less
tired before diagnosis [19.2±6.7, 21.6±8.0, respectively;
t (1, 272)=2.61, p<0.01], more tired 1 month after diagnosis
[t (1, 215)=2.51, p<0.05], and equally tired 3 and 6 months
after diagnosis.
In the BC group, fatigue measured at T2–T4 was not
associated with tumor group (p>0.05). At T3, patients who
were treated with radiotherapy were more tired [t (1, 189)=
2.30, p<0.05]. No differences for fatigue were found on other
measurement points or with chemotherapy or hormone
therapy.
After Bonferonni correction, the association between
demographics and fatigue in the BC and BBP group was
not significant for age (continuous), age >60 years, educa-
tion level, having children, having a paid job, and having a
partner. There were no personality differences between the
Table 1 Demographic and medical characteristics of the breast cancer








Having children 84 (68.9%) 92 (52.0%)







Paid work 41 (33.6%) 97 (54.8%)





a Data are expressed as mean±SD.
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BC and BBP group [Wilks Lambda=0.95, F(5, 228)=2.20,
p=0.055, partial eta squared 0.05]. In the total group,
women were more tired over time when they were more
neurotic, less agreeable, or more introverted (see Table 2
and Fig. 2). Neuroticism had a large effect size (partial eta
squared 0.27). There was no interaction between neuroti-
cism and extraversion (p>0.05). Because the BC and BBP
groups did not differ from each other with regard to
personality, the women scoring high on fatigue were not
only women with BC. In addition, fatigue in low
conscientious women changed over time: after an increase
at T2 and T3, the scores returned to baseline level (see
Fig. 3).
The regression analyses showed that before including
depressive symptoms into the analysis, neuroticism (β=0.45,
p<0.001) and extraversion (β=−0.27, p<0.05) were the only
predictors of fatigue at T4, explaining 48% of the variance.
When depressive symptoms were included in the third step,
baseline depressive symptoms (β=0.29, p<0.05), neuroti-
cism (β=0.29, p<0.05), and extraversion (β=−0.25, p<0.05)
predicted fatigue 6 months later, explaining 52% of the
variance. With baseline fatigue added to the regression
equation, only neuroticism (β=0.22, p<0.05) and baseline
fatigue (β=0.79, p<0.001) predicted fatigue, explaining 70%
of the variance. Demographic characteristics, diagnosis, and
adjuvant therapy (chemotherapy, radiotherapy, hormone
therapy) did not play a role.
Discussion
The aim of the study was to examine the relationship
between personality factors and fatigue in patients having a
palpable lump in the breast or being recalled for further
examination after an abnormality on a screening mammog-
raphy. The BC patients feel more tired after treatment had
started, but their fatigue levels return to baseline value after
a few months. In the total group, low scorers on
extraversion and agreeableness and high scorers on neurot-
icism showed a stable high fatigue level. After controlling
for depressive symptoms, neuroticism and extraversion
predicted fatigue 6 months later. When baseline fatigue
was included in the analysis, extraversion was not a
significant predictor anymore. Future research could study
underlying mechanisms to generate ideas for interventions.
In addition, other fatigue-related factors, such as anxiety
and sleep quality, that could mediate the relationship
between personality and fatigue, should also get attention.
In line with earlier research, several months after
diagnosis, fatigue was mild in severity in a majority of
the BC patients [2]. In line with Smets et al. [26] and
Greenberg et al. [13], just after radiation therapy, fatigue
was increased but returned quickly to baseline level. This
also explains why receiving adjuvant therapy did not
predict fatigue 6 months after surgical treatment. It might
be that fatigue, like subjective well-being [14], is only
temporarily affected by a major life event, such as being
diagnosed with and treated for cancer. Another possible
explanation is the response-shift phenomenon: patients get
used to increased levels of fatigue and reset their internal
standards [13, 27].
Personality was the main interest. Our findings not only
show that fatigue is quite stable in these women. Person-
ality seems to have a sound influence on the experienced
level of fatigue, irrespective of demographic or medical
factors or depressive symptoms. As was already found in
earlier studies [29, 30], extraversion and neuroticism were
predictors of fatigue. Smets et al. [25] suggested that the
link between neuroticism and fatigue could be explained by
Table 2 Differences in personality characteristics (scoring high or not
high on a factor) and the influence on fatigue scores over time
Personality
characteristics
df F p Partial eta
squared
Extraversion 1 5.03 0.026 0.04
Agreeableness 1 7.59 0.007 0.05
Conscientiousness 1 3.90 0.050 0.03
Neuroticism 1 48.76 0.000 0.27
Openness 1 0.49 0.49 0.004
Fig. 1 Course of fatigue over
6 months in women with benign
breast problems or cancer
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the fact that individuals high in negative affect report more
symptoms, probably due to their inner fixation and the
tendency to interpret symptoms as threatening. Neuroticism
and depressive symptoms were indeed found to be related in
several studies [6, 17]. Our findings did not support this idea
because after adding baseline depressive symptoms and
baseline fatigue, neuroticism remained a predictor. In the
study by Sugawara et al. [30], neuroticism was associated
with fatigue, independent of depressive symptoms. Different
measurement methods of personality and depression, number
of measurement points, and type of patients might explain
these conflicting findings. Neuroticism is characterized by
several constructs, such as anxiety and anger hostility. These
various constructs might relate differently to fatigue and
depression. Our personality measure could not differentiate
between the various components of neuroticism. Future
studies could examine this further.
Some explanations for the relationship between extra-
version and fatigue have been raised. Extraversion can be
partially defined as being energetic. The NEO-FFI extra-
version factor consists of several facets, and one of these is
labelled activity. Fatigue in cancer patients has often been
defined as lack of energy [31]. In contrast, this extraversion
facet denotes employing a lot of various daily activities. A
low scorer on this facet prefers a more relaxed life style,
which does not refer to being unenergetic. Nevertheless,
cancer-related fatigue and daily activity are inversely
related [1]. Thus, one of the possible connections between
extraversion and fatigue might be mediated by potential
amount of daily activity. Secondly, another NEO-facet of
extraversion-labelled positive emotions is strongly associ-
ated with happiness and well-being. Fatigue is a distressing
symptom in cancer patients, thereby impairing QOL [26,
29]. Being cheerful might also be the mediating link
between extraversion and fatigue.
Baseline fatigue was not only associated with extraver-
sion but also with depressive symptoms. The relationship
between depressive symptoms and fatigue has often been
found because fatigue is one of the symptoms of depres-
sion. However, in the present study, items of the CES-D
and the FAS loaded on two different factors (data not
shown), as in the development phase of the FAS [19]. This
is in line with a study on BC survivors [5], in which
fatigue, instead of being secondary to depression, co-
occurred with depression as part of a coordinated response
elicited by cytokine actions of the central nervous system.
Before diagnosis was known, the BC group was less tired
than the BBP group. Although the BC group was older than
the BBP group and more women from the latter group had
paid work, neither age nor having paid work was associated
with fatigue scores. Furthermore, fatigue was also unrelated
to the other demographic. Results of previous studies are
inconsistent at this point. We do not have an explanation for
the lower fatigue scores in the BC patients before diagnosis.
Like demographic factors and adjuvant therapy, diagno-
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Low conscientious
High conscientious
Fig. 3 Course of fatigue over
6 months in women scoring low
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Low extraverted
High extraverted
Fig. 2 Course of fatigue over
6 months in women scoring low
or high on extraversion
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finding might be the fact that fatigue scores at T4 had
returned to baseline level. Another explanation might be
that studies reporting that demographic factors, adjuvant
therapy, and/or diagnosis explained fatigue scores did not
examine personality factors, which appear to play an
important role in fatigue. Concerning demographic charac-
teristics, previous studies that included personality also
found that age, education level, and/or marital status did not
predict fatigue scores, especially when they had to compete
with other predictors in a model.
We did not measure fatigue in women with large tumors.
This study focussed on women with T1–T3 stage and women
with a benign breast disease, with the diagnosis being made
after entrance into the study. Therefore, we focussed on
women with smaller tumors and not, for instance, on women
with T4 stage. We did not intend to examine the differences in
fatigue between BC patients with different stages of diseases.
It might well be that fatigue levels are higher in women with
large tumors, as for example, these women often have
metastases and have chemotherapy for a considerable length
of time. We did not examine this, but future research on this
topic seems relevant.
One important limitation of the present study is the fact
that the FAS has not been validated in cancer patients.
However, internal consistency and factorial structure are
good, and because in the BBP group there was a high
correlation (r=0.91) between fatigue at 3 and 6 months,
test–retest reliability also appeared good. Furthermore, the
response rate is approximately 62%, which is comparable
with other studies [18] that include patients before
diagnosis is known. This is probably caused by feelings
of uncertainty or stress surrounding the diagnosis. These
feelings were also the reason for a number of women for
not participating in the study. The dropout rate was higher
in the BBP group. The patients who did not complete the
study were similar to the patients who remained in the study
on any factor. The main reason for dropout in the BBP group
was that patients no longer wanted to be confronted with
their visit to the hospital. In the BC group, stress was the
main reason for dropping out of the study.
To conclude, personality, especially neuroticism, is more
strongly related to fatigue than demographics, the diagnosis
cancer, receiving cancer treatment, and baseline depressive
symptoms and fatigue. When replicated, screening and
treating women who are at risk to experience high levels of
fatigue is recommended.
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